1) Strategy & Leadership
- DaVita's strategy is focused on improving patient outcomes and financial results, with a strong emphasis on clinical execution and innovation in dialysis.
- The company is transitioning phosphate binders into the Medicare dialysis bundle, enhancing access to better therapies for patients.
- CEO Javier Rodriguez highlighted the importance of the recent clearance of middle molecules and the company's commitment to elevating the standard of care.

2) Financial & Segment Results
- Q2 adjusted operating income was $579 million, with adjusted earnings per share at $4.02 and free cash flow of $256 million.
- U.S. dialysis treatments increased by 56 basis points year-over-year, with expectations for treatment growth near the top end of the previous guidance range of 25 to 50 basis points for 2026.
- Revenue per treatment declined by approximately $2 sequentially, primarily due to a lower commercial mix and phosphate binder revenue. Year-to-date revenue per treatment is up 3.6% compared to the first half of 2025.
- Patient care costs per treatment declined by $3 sequentially, but year-to-date costs have grown by over 3% compared to the first half of 2025.

3) Problems / Headwinds
- The proposed Medicare payment update for 2027 is complex and expected to track below industry cost trends, which could impact financial performance.
- There was a decline in commercial mix due to the expiration of ACA subsidies, leading to a projected $40 million headwind for the year.
- Missed treatments were elevated, and the company experienced fewer admits from closed Fresenius clinics, impacting volume growth expectations.

4) Operational or Product Plans
- DaVita plans to deploy expanded hemodialysis (HD) broadly across its network, leveraging new FDA-approved dialyzers that improve middle molecule clearance.
- The company has secured sufficient supply of expanded HD dialyzers to meet demand, enhancing operational efficiency and patient care.
- The IKC segment is expected to contribute positively to operating income growth, with ongoing efforts to manage total care costs effectively.

5) Guidance & Outlook / Investor Angle
- DaVita reaffirmed its full-year 2026 guidance with a midpoint of $2.2 billion for adjusted operating income and $14.65 for adjusted earnings per share.
- The company anticipates a sequential increase in adjusted operating income of $50 million to $100 million from Q3 to Q4, driven by the IKC segment.
- The focus remains on clinical strategies that enhance patient outcomes, which are expected to support volume growth and financial performance moving forward.

Bottom line: DaVita is positioned for continued growth through strategic clinical innovations and operational efficiencies, despite facing headwinds from regulatory changes and market dynamics. The reaffirmed guidance reflects confidence in its ability to navigate these challenges while enhancing patient care and financial performance.